#ITI#Field evaluation of tylosin premix in layers previously vaccinated with a live mycoplasma gallisepticum vaccine#FTI#
#IRE#Mycoplasma gallisepticum infection results in numerous clinical signs including a reduction in egg production in laying chickens. Attempts to prevent mycoplasmosis have included vaccination with both killed and attenuated live M. gallisepticum strains. Live vaccines provide reduction in clinical signs and have been shown to replace indigenous strains when used in a consistent program for several placements. Antibiotic therapy is another option for controlling losses associated with mycoplasmosis. Therapeutic antibiotics with activity against mycoplasma approved for use in poultry include tetracyclines and tylosin. These drugs also are approved for feed efficiency when administered in the feed at levels below the therapeutic index for mycoplasma. The data presented here suggest that birds vaccinated with the live 6/85 strain of M. gallisepticum and then fed tylosin, at the approved level for feed efficiency, exhibit a serologic vaccine response similar to that of unmedicated birds but show improved feed efficiency.#FRE#
#IPC#Live vaccine; Mycoplasma galllsepticum; Tylosin#FPC#
#IRF#Feed additive compendium, (2001); 
Angulo F.J., Johnson K.R., Tauxe R.V., Cohen M.L., Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella: Implications for the use of fluoroquinolones in food animals, Microb. Drug Resist., 6, pp. 77-83, (2000); 
Arzey G.G., Arzey K.E., Successful treatment of mycoplasmosis in layer chickens with single dose therapy, Aust. Vet. J., 69, pp. 126-128, (1992); 
Barbour E.K., Hamadeh S.K., Eidt A., Infection and immunity in broiler chicken breeders vaccinated with a temperature-sensitive mutant of Mycoplasma gallisepticum and impact on performance of offspring, Poult. Sci., 79, pp. 1730-1735, (2000); 
Barbour E.K., Newman J.A., Comparison of Mycoplasma gallisepticum subunit and whole organism vaccines containing different adjuvants by western immunoblotting, Vet. Immunol. Immunopathol., 2, pp. 135-144, (1989); 
Branton S.L., Lott B.D., May J.D., Maslin W.R., Pharr G.T., Bearson S.D., Collier S.D., Boykin D.L., The effects of ts-11 strain Mycoplasma gallisepticum vaccination in commercial layers on egg production and selected egg quality parameters, Avian Dis., 44, pp. 618-623, (2000); 
Carpenter T.E., Mallinson E.T., Miller K.F., Gentry R.F., Swartz L.D., Vaccination with F-strain MG to reduce production losses in layer chickens, Avian Dis., 25, pp. 404-409, (1981); 
Carpenter T.E., Miller K.F., Gentry R.F., Swartz L.D., Mallinson E.T., Control of Mycoplasma gallisepticum in commercial laying chickens using artificial exposure to Connecticut F strain Mycoplasma gallisepticum, Proc. 83rd Annual Meeting of the United States Animal Health Association, pp. 364-370, (1979); 
Cohen M.L., Tauxe R.V., Drug-resistant Salmonella in the United States: An epidemiologic perspective, Science, 234, pp. 964-969, (1986); 
Cooper A.C., Fuller J.R., Fuller M.K., Whittlestone P., Wise D.R., In vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance, Res. Vet. Sci., 54, pp. 329-334, (1993); 
Cummings T.S., Kleven S.H., Evaluation of protection against MG infection in chickens vaccinated with the F strain of MG, Avian Dis., 30, pp. 169-171, (1986); 
Evans R.D., Hafez Y.S., Evaluation of a Mycoplasma gallisepticum strain exhibiting reduced virulence for prevention and control of poultry mycoplasmosis, Avian Dis., 36, pp. 197-201, (1992); 
Evans R.D., Hafez Y.S., Orthel F.W., Mycoplasma gallisepticum vaccination-challenge; an egg production model, Avian Dis., 36, pp. 956-963, (1992); 
Fey P.D., Safranek T.J., Rupp M.E., Dunne E.F., Ribot E., Iwen P.C., Bradford P.A., Angulo F.J., Hinrichs S.H., Ceftriaxone-resistant salmonella infection acquired by a child from cattle, N. Engl. J. Med., 342, pp. 1242-1249, (2000); 
Hagan W.A., Bruner B.C., The genera Mycoplasma and Ureaplasma, Microbiology and infectious diseases of domestic animals, 8th ed., pp. 312-313, (1988); 
Hannan P.C.T., O'Hanlon P.J., Rogers N.H., In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens, Res. Vet. Sci., 46, pp. 202-211, (1989); 
Jordan F.T., Forrester C.A., Hodge A., Reeve-Johnson L.G., The comparison of an aqueous preparation of tilmicosin with tylosin in the treatment of Mycoplasma gallisepticum infection of turkey poults, Avian Dis., 43, pp. 521-525, (1999); 
Jordan F.T., Forrester C.A., Ripley P.H., Burch D.G., In vitro and in vivo comparisons of valnemulin, tiamulin, tylosin, enrofloxacin, and lincomycin/spectinomycin against Mycoplasma gallisepticum, Avian Dis., 42, pp. 738-745, (1998); 
Jordan F.T., Horrocks B.K., Jones S.K., Cooper A.C., Giles C.J., A comparison of the efficacy of danofloxacin and tylosin in the control of Mycoplasma gallisepticum infection in broiler chicks, J. Vet. Pharmacol. Ther., 16, pp. 79-86, (1993); 
Kempf I., Gesbert F., Guittet M., Bennejean G., Mycoplasma gallisepticum infection in drug-treated chickens: Comparison of diagnosis methods including polymerase chain reaction, Zentralbl. Veterinaermed Reihe B, 41, pp. 597-602, (1994); 
Kleven S.H., Changing expectations in the control of Mycoplasma gallisepticum, Acta Vet. Hung., 45, pp. 299-305, (1997); 
Kleven S.H., Mycoplasmas in the etiology of multifactorial respiratory disease, Poult. Sci., 77, pp. 1146-1149, (1998); 
Kleven S.H., Fan H.H., Turner K.S., Pen trial studies on the use of live vaccines to displace virulent Mycoplasma gallisepticum in chickens, Avian Dis., 42, pp. 300-306, (1998); 
Levisohn S., Kleven S.H., Avian mycoplasmosis (Mycoplasma gallisepticum), Rev. Sci. Tech., 19, pp. 425-442, (2000); 
Lin M.Y., Chiang Y.C., Lin K.Y., Sung H.T., Susceptibility of avian mycoplasmas isolated in Taiwan to 21 antimicrobial agents, Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi, 27, pp. 70-79, (1994); 
Mohammed H.O., Carpenter T.E., Yamamoto R., Economic impact of MG and MS in commercial layer flocks, Avian Dis., 31, pp. 477-489, (1987); 
Namgoong S., An S.H., Rhee Y.O., Kim K.S., Park K.S., Research reports of the office of rural development (livestock), Suweon, Korea, 23, pp. 143-151, (1981); 
Ose E.E., Wellenreiter R.H., Tonkinson L.V., Effects of feeding tylosin to layers exposed to Mycoplasma gallisepticum, Poult. Sci., 58, pp. 42-49, (1979); 
Panigrahy B., Grumbles L.C., Hall C.R., Immunogenic potency of oil-emulsified Mycoplasma gallisepticum bacterins, Avian Dis., 25, pp. 821-826, (1981); 
Prier J.E., Dart G., Immunological and serological studies on infectious sinusitis of turkeys, Cornell Vet., 41, pp. 38-46, (1951); 
Rimmler R.B., Davis R.B., Page R.K., Kleven S.H., Infectious coryza: Preventing complicated coryza with Haemophilus gallinarum and Mycoplasma gallisepticum bacterins, Avian Dis., 22, pp. 140-150, (1978); 
Roney C.S., Evans R.D., Further studies on live MG vaccine strain 6/85, Proc. Western Poultry Disease Conference, (1993); 
Roney C.S., Evans R.D., Storm P.K., The 6/85 strain: A new live vaccine for Mycoplasma gallisepticum, Proc. Western Poultry Disease Conference, (1992); 
Tanner A.C., Wu C.C., Adaptation of the sensititre broth microdilution technique to antimicrobial susceptibility testing of Mycoplasma gallisepticum, Avian Dis., 36, pp. 714-717, (1992); 
Turner K.S., Kleven S.H., Eradication of live F strain Mycoplasma gallisepticum vaccine using live ts-11 on a multiage commercial layer farm, Avian Dis., 42, pp. 404-407, (1998); 
Van der Heide L., Vaccination can control costly chronic respiratory disease in poultry, (1977); 
Watkins K., Shryock T., Dearth R., Saif Y., In-vitro antimicrobial susceptibility of Clostridium perfringens from commercial turkey and broiler chicken origin, Vet. Microbiol., 54, pp. 195-200, (1997); 
Whithear K.G., Control of avian mycoplasmas by vaccination, Rev. Sci. Tech., 15, pp. 1527-1553, (1996); 
Whithear K.G., Bowtell D.D., Ghiocas E., Hughes K.L., Evaluation and use of a microbroth dilution procedure for testing sensitivity offermentative avian mycoplasmas to antibiotics, Avian Dis., 27, pp. 937-949, (1983); 
Whithear K.G., Soeripto, Harrigan K.E., Ghiocas E., Immunogenicity of a temperature sensitive mutant Mycoplasma gallisepticum vaccine, Aust. Vet. J., 67, pp. 168-174, (1990); 
Yoder Jr. H.W., Serologic response of chickens vaccinated with inactivated preparations of Mycoplasma gallisepticum, Avian Dis., 23, pp. 493-506, (1979); 
Yoder Jr. H.W., Avian mycoplasmas, Diagnostic procedures in veterinary bacteriology and mycology, 5th ed., pp. 334-341, (1990); 
Yoder Jr. H.W., Mycoplasma gallisepticum infections, Diseases of poultry, 9th ed., pp. 198-212, (1991)#FRF#
